Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891318902> ?p ?o ?g. }
- W2891318902 endingPage "1832" @default.
- W2891318902 startingPage "1824" @default.
- W2891318902 abstract "Abstract The broadly active glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON) has been studied for 60 years as a potential anticancer therapeutic. Clinical studies of DON in the 1950s using low daily doses suggested antitumor activity, but later phase I and II trials of DON given intermittently at high doses were hampered by dose-limiting nausea and vomiting. Further clinical development of DON was abandoned. Recently, the recognition that multiple tumor types are glutamine-dependent has renewed interest in metabolic inhibitors such as DON. Here, we describe the prior experience with DON in humans. Evaluation of past studies suggests that the major impediments to successful clinical use included unacceptable gastrointestinal (GI) toxicities, inappropriate dosing schedules for a metabolic inhibitor, and lack of targeted patient selection. To circumvent GI toxicity, prodrug strategies for DON have been developed to enhance delivery of active compound to tumor tissues, including the CNS. When these prodrugs are administered in a low daily dosing regimen, appropriate for metabolic inhibition, they are robustly effective without significant toxicity. Patients whose tumors have genetic, metabolic, or imaging biomarker evidence of glutamine dependence should be prioritized as candidates for future clinical evaluations of novel DON prodrugs, given either as monotherapy or in rationally directed pharmacologic combinations. Mol Cancer Ther; 17(9); 1824–32. ©2018 AACR." @default.
- W2891318902 created "2018-09-27" @default.
- W2891318902 creator A5023686004 @default.
- W2891318902 creator A5045645746 @default.
- W2891318902 creator A5076813849 @default.
- W2891318902 creator A5090359406 @default.
- W2891318902 date "2018-09-01" @default.
- W2891318902 modified "2023-10-17" @default.
- W2891318902 title "We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of <i>6-Diazo-5-oxo-L-norleucine</i>" @default.
- W2891318902 cites W1243294255 @default.
- W2891318902 cites W1438529674 @default.
- W2891318902 cites W1529544307 @default.
- W2891318902 cites W1550736140 @default.
- W2891318902 cites W1589007430 @default.
- W2891318902 cites W1655763950 @default.
- W2891318902 cites W1969767350 @default.
- W2891318902 cites W1974684460 @default.
- W2891318902 cites W1976722667 @default.
- W2891318902 cites W1986895669 @default.
- W2891318902 cites W1989158891 @default.
- W2891318902 cites W1990780055 @default.
- W2891318902 cites W1992811920 @default.
- W2891318902 cites W1996365670 @default.
- W2891318902 cites W2014128464 @default.
- W2891318902 cites W2014988241 @default.
- W2891318902 cites W2034369179 @default.
- W2891318902 cites W2038652783 @default.
- W2891318902 cites W2041729369 @default.
- W2891318902 cites W2042680956 @default.
- W2891318902 cites W2050713515 @default.
- W2891318902 cites W2051181260 @default.
- W2891318902 cites W2056174640 @default.
- W2891318902 cites W2062824332 @default.
- W2891318902 cites W2063076216 @default.
- W2891318902 cites W2064583158 @default.
- W2891318902 cites W2065333824 @default.
- W2891318902 cites W2066758197 @default.
- W2891318902 cites W2070001923 @default.
- W2891318902 cites W2072451938 @default.
- W2891318902 cites W2074873270 @default.
- W2891318902 cites W2086816631 @default.
- W2891318902 cites W2093678197 @default.
- W2891318902 cites W2097483643 @default.
- W2891318902 cites W2099320952 @default.
- W2891318902 cites W2110508238 @default.
- W2891318902 cites W2112861594 @default.
- W2891318902 cites W2120188820 @default.
- W2891318902 cites W2123734813 @default.
- W2891318902 cites W2127643721 @default.
- W2891318902 cites W2132117833 @default.
- W2891318902 cites W2149218373 @default.
- W2891318902 cites W2168452425 @default.
- W2891318902 cites W2290466312 @default.
- W2891318902 cites W2295182096 @default.
- W2891318902 cites W2395800464 @default.
- W2891318902 cites W2400766008 @default.
- W2891318902 cites W2412552789 @default.
- W2891318902 cites W2416837437 @default.
- W2891318902 cites W2417803418 @default.
- W2891318902 cites W2436260614 @default.
- W2891318902 cites W2466657954 @default.
- W2891318902 cites W2467968452 @default.
- W2891318902 cites W2503851771 @default.
- W2891318902 cites W2515129893 @default.
- W2891318902 cites W2516129687 @default.
- W2891318902 cites W2519688808 @default.
- W2891318902 cites W2556906723 @default.
- W2891318902 cites W2568414132 @default.
- W2891318902 cites W2580528384 @default.
- W2891318902 cites W2590313625 @default.
- W2891318902 cites W2601158320 @default.
- W2891318902 cites W2606822414 @default.
- W2891318902 cites W2715137823 @default.
- W2891318902 cites W2729334679 @default.
- W2891318902 cites W2730941312 @default.
- W2891318902 cites W2739558775 @default.
- W2891318902 cites W2759230072 @default.
- W2891318902 cites W2764232556 @default.
- W2891318902 cites W4255273898 @default.
- W2891318902 cites W9686781 @default.
- W2891318902 doi "https://doi.org/10.1158/1535-7163.mct-17-1148" @default.
- W2891318902 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6130910" @default.
- W2891318902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30181331" @default.
- W2891318902 hasPublicationYear "2018" @default.
- W2891318902 type Work @default.
- W2891318902 sameAs 2891318902 @default.
- W2891318902 citedByCount "129" @default.
- W2891318902 countsByYear W28913189022018 @default.
- W2891318902 countsByYear W28913189022019 @default.
- W2891318902 countsByYear W28913189022020 @default.
- W2891318902 countsByYear W28913189022021 @default.
- W2891318902 countsByYear W28913189022022 @default.
- W2891318902 countsByYear W28913189022023 @default.
- W2891318902 crossrefType "journal-article" @default.
- W2891318902 hasAuthorship W2891318902A5023686004 @default.
- W2891318902 hasAuthorship W2891318902A5045645746 @default.
- W2891318902 hasAuthorship W2891318902A5076813849 @default.
- W2891318902 hasAuthorship W2891318902A5090359406 @default.